Jean Chang

Oversee business development function: identifying opportunities, assessing cost/benefit, risks and presenting opportunities for partnership or evaluation; structure and negotiate partnership agreements. Negotiate and obtain access to value-adding technologies for Dynavax’s broader immuno-oncology portfolio. Strategy and execution of clinical-stage oncology programs. Lead cross-functional development team for Phase 1/2 immuno-oncology program.

Led product launch of Savella® for the treatment of fibromyalgia in collaboration with Forest Labs. Responsible for developing positioning, branding, pricing and other compliant marketing strategies, and for rollout with a field sales organization of 100 reps. Performed multiple in-licensing evaluations with a focus on strategic implications, including target product profile, competitive analysis and revenue forecasts.

Commercial development of a novel Phase 2/3 compound for in-patient post-operative and chronic pain indications. Key member of business development team assessing commercial opportunities of M&A targets with late-stage products that led to successful reverse merger. Conducted commercial review to support selection of follow-on indications in IBD, asthma and oncology markets for Phase I/II eczema clinical candidate.